United States Seeks Delay In Trial On Us Air, Amr Deal Due To Shutdown

Teva Announces Launch of Generic Zemplar(R) in the United States

In approximately 3 months, United States Cellular has returned 19.45% as of today’s recent price of $45.87. United States Cellular share prices have moved between a 52-week high of $45.91 and a 52-week low of $32.25 and are now trading 42% above that low price at $45.87 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.8%. United States Cellular Corporation provides cellular telephone service throughout the United States. SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of United States Cellular shares. Log in and add United States Cellular (USM) to your watchlist today so you can receive a real-time alert when the shares are about to change trend. Keywords: spotlights amex:usm united states cellular Contact Nick Russo Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com . Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup .

U.S. Airways jets are seen at Reagan National Airport in Washington July 12, 2013. REUTERS/Larry Downing

Merging companies usually oppose delays because they make it harder to hold deals together. So it was good news for the airlines when Judge Colleen Kollar-Kotelly turned down the request in an order issued on Tuesday. A lawyer for the airlines expected the trial to begin as scheduled in late November. “From what the judge said in there, and I think everybody heard, we’re going to trial on November 25,” Richard Parker said after a pretrial hearing. “We are planning on a November 25 trial date.” Parker said a settlement resolving the fight was still possible. “We are interested in a reasonable settlement in this case,” he added. Any settlement would mean asset sales, which in turn would require approval from the judge overseeing American’s emergence from bankruptcy. TEXAS SECURES CONCESSIONS Under the agreement announced on Tuesday, the Dallas/Fort Worth International Airport would remain a hub for the combined carrier, whose headquarters would be in Texas. Almost two dozen small Texas airports would continue to get daily service, the Texas attorney general’s office said. Antitrust experts said that losing Texas from the suit was unlikely to affect the Justice Department’s ability to litigate to stop the deal. “The case will proceed without Texas and it will have no impact on the government without the state. I don’t think it will matter one way or another,” said Jonathan Lewis, an antitrust expert with Baker Hostetler. The airlines have defended the deal in court filings, saying it would create $500 million in savings to consumers annually by creating a stronger competitor to Delta Air Lines Inc (DAL.N) and United Continental Holdings Inc (UAL.N). But the Justice Department has said the merger would be bad for consumers.

United States Cellular Up 19.5% Since SmarTrend Uptrend Call (USM)

Marketed by AbbVie Inc., Zemplar(R) had annual sales of approximately $115 million in the United States, according to IMS data as of June 30, 2013. About Teva Teva Pharmaceutical Industries Ltd. /quotes/zigman/10294855/quotes/nls/teva TEVA -0.24% is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE(R) (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S.

Golf-Penpix of United States Presidents Cup team

Won his first World Golf Championships title at the Accenture Match Play Championship in February, then proved his comfort level with Muirfield Village by clinching the Memorial Tournament there in June. Previous Presidents Cup appearances: 2011 Presidents Cup record: 1-3-1 World Ranking: 15 PGA Tour victories: 3 Two years ago, Bradley was overlooked as a wildcard pick by U.S. captain Fred Couples just one month after winning his first major title at the PGA Championship. Bradley proved what might have been by shining on his Ryder Cup debut at Medinah last year. Clearly thrives when the pressure is at its most intense and is likely to be paired with his long-time mentor Mickelson. Previous Presidents Cup appearances: None – – World Ranking: 10 PGA Tour victories: 3 One of the most laidback figures in the game who has popularised the term ‘Dufnering,’ he produced superb form in the last two months of the 2013 PGA Tour with four top-10s, including a maiden major victory at the PGA Championship. Though a rookie, Dufner should be well suited to the Presidents Cup with his ice-cool demeanour and solid ball-striking. Previous Presidents Cup appearances: None – – World Ranking: 7 PGA Tour victories: 12 A PGA Tour veteran, Stricker produced one of his most successful seasons in 2013 despite playing a limited schedule to spend more time with his family. He posted eight top-10s in 13 starts, including four runner-up spots, and ended his campaign with the lowest adjusted scoring average (68.95). A brilliant putter, he can be paired with virtually anyone on the U.S. team. Previous Presidents Cup appearances: 1996, 2007, 2009, 2011 Presidents Cup record: 11-8-0 World Ranking: 28 PGA Tour victories: 5 A captain’s pick for the Presidents Cup two years ago, Haas earned automatic selection for this week on the way to a very consistent 2013 PGA Tour season that included a nine top-10s.